Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

6 novembre 2015 aggiornato da: Astellas Pharma Inc

A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

A study to assess the safety and efficacy of Alefacept in de novo kidney transplant patients.

Panoramica dello studio

Descrizione dettagliata

This is a 4 arm (all active) study to determine the safety and efficacy of Alefacept in de novo kidney transplant recipients.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

323

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Loma Linda, California, Stati Uniti, 92354
        • Loma Linda University Medical Center
      • Los Angeles, California, Stati Uniti, 90033
        • University of Southern California - University Hospital
      • Los Angeles, California, Stati Uniti, 90057
        • St. Vincent/National Institute of Transplantation
      • Sacramento, California, Stati Uniti, 95817
        • UC Davis Medical Center
      • San Diego, California, Stati Uniti, 92103
        • UCSD
      • San Diego, California, Stati Uniti, 92123
        • California Institute of Renal Research/Sharp Memorial Hospital
      • San Francisco, California, Stati Uniti, 94143
        • University of California - San Francisco
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • University of Colorado Health Science Center
    • Florida
      • Gainesville, Florida, Stati Uniti, 32610
        • University of Florida, Shands Hospital, Gainesville
      • Jacksonville, Florida, Stati Uniti, 32224
        • Mayo Clinic - Jacksonville
    • Georgia
      • Augusta, Georgia, Stati Uniti, 30921
        • Medical College of Georgia, Augusta
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • University of Illinois at Chicago
      • Chicago, Illinois, Stati Uniti, 60637
        • University Of Chicago Medical Center
      • Chicago, Illinois, Stati Uniti, 60612
        • Rush - Presbyterian - St. Lukes Medical Center
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40536
        • University of Kentucky
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21201
        • University of Maryland Center
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02115
        • Brigham and Women's Hospital
      • Boston, Massachusetts, Stati Uniti, 02111
        • Tufts Medical Center
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • University of Michigan
    • New Jersey
      • Livingston, New Jersey, Stati Uniti, 07039
        • St. Barnabas Medical Center
    • New York
      • Buffalo, New York, Stati Uniti, 14203
        • Buffalo General Hospital
      • New York, New York, Stati Uniti, 10029
        • Mt. Sinai School of Medicine
      • New York, New York, Stati Uniti, 10065
        • New York Presbyterian Hospital - Cornell
      • Valhalla, New York, Stati Uniti, 10595
        • Westchester Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27599
        • University of North Carolina
      • Durham, North Carolina, Stati Uniti, 27710
        • Duke University Medical Center
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44106
        • University Hospital of Cleveland
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Oregon Health & Science University
      • Portland, Oregon, Stati Uniti, 97210
        • Legacy Transplant Services
    • Pennsylvania
      • Harrisburg, Pennsylvania, Stati Uniti, 17101
        • Pinnacle Health at Harrisburg
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • University of Pennsylvania
    • Tennessee
      • Memphis, Tennessee, Stati Uniti, 38104
        • Methodist University Hospital - Memphis
    • Texas
      • Dallas, Texas, Stati Uniti, 75246
        • Baylor University Medical Center
      • Houston, Texas, Stati Uniti, 77030
        • Methodist Hospital Research Institute of Houston
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84132
        • University of Utah Medical Center
    • Virginia
      • Richmond, Virginia, Stati Uniti, 23298
        • Virginia Commonwealth University School of Medicine
    • Washington
      • Seattle, Washington, Stati Uniti, 98195
        • University of Washington Medical Center
    • Wisconsin
      • Madison, Wisconsin, Stati Uniti, 53792
        • University of Wisconsin Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Subject is anticipated to receive first oral dose of tacrolimus within 48 hours of transplant procedure
  • Subject is a recipient of a de novo kidney transplant
  • Subject is a recipient of a kidney from a non-human leukocyte antigen (HLA) identical related living donor, a non-related living donor, or a deceased donor

Exclusion Criteria:

  • Subject has a screening (pre-operative)estimated cluster of differentiation (CD) 4+ T-cell count of < 250 cells/µL
  • Subject will receive a kidney with an anticipated cold ischemia time (CIT) of > 30 hours
  • Recipient has a positive T or B-cell cross match by investigational site's standard method of determination
  • Subject will receive a kidney from a 50-65 year old deceased donor with one of the following:

    • History of hypertension and a terminal serum creatinine > 1.5 mg/dL
    • Cerebrovascular accident as cause of death and a terminal serum creatinine > 1.5 mg/dL
    • History of hypertension and cerebrovascular accident as cause of death and a terminal serum creatinine > 1.5 mg/dL

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Tacrolimus/MMF/Basiliximab
Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.
The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
Altri nomi:
  • Prograf, FK506
Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
Altri nomi:
  • Simuletto
Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
Altri nomi:
  • CellCept, MMF
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Sperimentale: Alefacept QW/Tacrolimus/MMF
Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.
The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
Altri nomi:
  • Prograf, FK506
Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
Altri nomi:
  • CellCept, MMF
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
Altri nomi:
  • Amevive, ASP0485
Sperimentale: Alefacept QW/Tacrolimus
Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.
The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
Altri nomi:
  • Prograf, FK506
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
Altri nomi:
  • Amevive, ASP0485
Sperimentale: Alefacept QOW/Tacrolimus/MMF
Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.
The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
Altri nomi:
  • Prograf, FK506
Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
Altri nomi:
  • CellCept, MMF
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
Altri nomi:
  • Amevive, ASP0485

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants With Biopsy-confirmed Acute Rejection (BCAR) at Month 6 Assessed by Local Review
Lasso di tempo: 6 months

Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.

The Kaplan-Meier estimates at Day 182 was used for the analyses at 6 months. Lost to follow-up or patients with missing outcomes were censored at their last follow up visit.

6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Patient Survival at Month 6 and Month 12
Lasso di tempo: 6 months and 12 months

Patient survival is any participant who is known to be alive 6 months and 12 months after the skin closure date.

The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

6 months and 12 months
Graft Survival at Month 6 and Month 12
Lasso di tempo: 6 months and 12 months

Graft survival was defined as any participant who was known to have a functioning graft (i.e., not graft loss) at 6 months and 12 months after the skin closure date. Graft loss was defined as patient death, retransplant, permanent return to dialysis (dialysis greater than 30 days) or transplant nephrectomy.

The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

6 months and 12 months
Percentage of Participants With BCAR at Month 12 Assessed by Local Review
Lasso di tempo: 12 months

Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.

The Kaplan-Meier estimates at Day 365 was used for the analyses at 12 months. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

12 months
Percentage of Participants With BCAR at Month 6 and 12 Assessed by Central Review
Lasso di tempo: 6 months and 12 months

Rejection episodes were confirmed by biopsy by a central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.

The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

6 months and 12 months
Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Local Review
Lasso di tempo: 6 months and 12 months

Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR.

The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

6 months and 12 months
Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Central Review
Lasso di tempo: 6 months and 12 months

Rejection episodes were confirmed by biopsy by the central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR.

The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

6 months and 12 months
Change From Week 4 in Glomerular Filtration Rate Estimated by the MDRD Method at Month 6 and Month 12
Lasso di tempo: Week 4, Month 6 and Month 12
The glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) method.
Week 4, Month 6 and Month 12
Change From Week 4 in GFR by Iothalamate Clearance at Month 6
Lasso di tempo: Week 4 and Month 6
The glomerular filtration rate was measured directly using iothalamate clearance.
Week 4 and Month 6
Change From Week 4 in Serum Creatinine at Month 6 and 12
Lasso di tempo: Week 4 and Month 6 and 12
Week 4 and Month 6 and 12
Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Local Review
Lasso di tempo: 6 months and 12 months
Efficacy failure is defined as death, graft failure (permanent return to dialysis [>30 days] or retransplant), BCAR according to local review, or lost to follow-up.
6 months and 12 months
Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Central Review
Lasso di tempo: 6 months and 12 months
Efficacy failure is defined as death, graft failure (permanent return to dialysis [>30 days] or retransplant), BCAR according to central review, or lost to follow-up.
6 months and 12 months
Time to First BCAR Assessed by Local Review
Lasso di tempo: 12 months
The time to first BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a BCAR are included in the analysis.
12 months
Time to First BCAR Assessed by Central Review
Lasso di tempo: 12 months
The time to first BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a BCAR are included in the analysis.
12 months
Time to First T-cell Mediated BCAR Assessed by Local Review
Lasso di tempo: 12 months
The time to first T-cell mediated BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1.
12 months
Time to First T-cell Mediated BCAR Assessed by Central Review
Lasso di tempo: 12 months
The time to first T-cell mediated BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a T-cell mediated BCAR are included in the analysis.
12 months
Maximum Grade of T-cell Mediated Rejection Assessed by Local Review
Lasso di tempo: 6 months and 12 months

The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis.

Grade IA: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising >25% of the luminal area; Grade III: Cases with "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.

6 months and 12 months
Maximum Grade of T-cell Mediated Rejection as Assessed by Central Review
Lasso di tempo: 6 months and 12 months

The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis.

Grade IA: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising >25% of the luminal area; Grade III: Cases with "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.

6 months and 12 months
Percentage of Participants With Clinically Treated Acute Rejection at Month 6 and Month 12
Lasso di tempo: 6 months and 12 months
Patients who received immunosuppressive medications for the treatment of suspected or BCAR were considered to have a clinically-treated acute rejection.
6 months and 12 months
Percentage of Participants With Anti-lymphocyte-treated Rejection at Months 6 and 12
Lasso di tempo: 6 months and 12 months

Participants with histologically proved Banff Grade II or III rejection could receive anti-rejection therapy with anti-lymphocyte antibodies per institutional protocol.

The use of anti-lymphocyte antibody therapy at any time during a suspected or proven rejection episode for the treatment of acute rejection was considered an event.

6 months and 12 months
Percentage of Participants With Multiple Rejection Episodes at Months 6 and 12
Lasso di tempo: 6 months and 12 months
All participants were evaluated for the incidence of multiple rejection episodes (clinically treated and/or BCAR as assessed by the local reviewer) through 6 months and 12 months.
6 months and 12 months
Percentage of Participants With Treatment Failure at Month 6 and 12
Lasso di tempo: 6 months and 12 months
Treatment failure was defined as death, graft loss, BCAR (local review), lost to follow-up or early discontinuation of treatment regimen. The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.
6 months and 12 months
Gastrointestinal Quality of Life Index Score Over Time
Lasso di tempo: Months 1, 3, 6, and 12
The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Quality of Life Index (GIQLI) symptom severity score. The GIQLI is a 36-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past 2 weeks on a scale from 0 (all of the time) to 4 (never). Possible overall scores ranged from 0 to 4, with higher scores indicating a better quality of life according to the different symptomatic criteria.
Months 1, 3, 6, and 12
Gastrointestinal Symptom Rating Scale Scores Over Time
Lasso di tempo: Months 1, 3, 6, and 12
The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Symptom Rating Scale Scores (GSRS). The GSRS a 15-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past week on a scale from 1 (no discomfort at all) to 7 (very severe discomfort). Possible overall scores range from 1 to 7, with lower scores indicating a better quality of life with respect to gastrointestinal symptoms.
Months 1, 3, 6, and 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Principal Investigator, University of Michigan

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 febbraio 2008

Completamento primario (Effettivo)

1 febbraio 2011

Completamento dello studio (Effettivo)

1 febbraio 2011

Date di iscrizione allo studio

Primo inviato

11 ottobre 2007

Primo inviato che soddisfa i criteri di controllo qualità

12 ottobre 2007

Primo Inserito (Stima)

15 ottobre 2007

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

11 dicembre 2015

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2015

Ultimo verificato

1 novembre 2015

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi